Background: Patients who have asthma-related emergency department (ED) visits or hospitalizations are at risk for recurrent exacerbation events. Our objectives were to assess whether receiving a controller medication at discharge affects risk of recurrence and whether delaying controller initiation alters this risk. Methods: Asthma patients with an ED visit or inpatient (IP) stay who received a controller dispensing within 6 months were identified from healthcare claims. Cox proportional hazards of the time to first recurrence of an asthma-related ED or IP visit in the 6-month period following the initial event were constructed, with time following discharge without controller medication as the primary predictor. Results: A total of 6139 patients met inclusion criteria, 78% with an ED visit and 22% with an IP visit; 15% had a recurrence within 6 months. The adjusted hazard ratio (HR) associated with not having controller medication at discharge was 1.79 (95% confidence interval [CI], 1.42 e2.25). The controller-by-time interaction was significant (P < 0.001), with hazard rising as time-to-controller initiation increased. Delaying initiation by 1 day approximately tripled the risk (HR 2.95; 95%CI 1.48e5.88). Sensitivity analyses, including accounting for controller fills prior to the index event, did not substantially alter these results.
Introduction
Asthma exacerbations are acute episodes of symptom worsening. Mild exacerbations are typically managed with quick-relief medications at home, 1 but more severe exacerbations may necessitate a physician office visit, emergency department (ED) visit, or hospitalization.
1,2 United States national survey data indicate that patients had approximately 1.75 million asthma-related ED visits and 456,000 hospitalizations in 2007. 3 Asthma patients who have ED visits or hospitalizations due to exacerbations are at risk for recurrent events. 4e6 Therefore, practice guidelines recommend that physicians provide a discharge plan including measures to prevent future exacerbations as well as to address the current exacerbation.
1,2 ED and hospital physicians should consider prescribing a long-term controller medication at discharge, such as an inhaled corticosteroid (ICS), for patients who do not currently use a controller, in addition to continued short-term treatment with a short-acting beta-agonist (SABA) and systemic corticosteroids. 1, 2, 7 Controller use after an acute event has been shown to help prevent repeat asthma-related ED visits and hospitalizations. 8e12 Sin et al. 10 showed that patients who used an ICS after discharge from asthma-related ED visits had 45% fewer subsequent ED visits over follow-up of at least 2 years. Rowe et al. 12 reported that the proportion of patients that had healthcare visits in the 3 weeks following ED treatment for an acute asthma event was lower for those who were randomly assigned to receive budesonide versus placebo upon discharge. In other analyses, children who used inhaled budesonide within 30 days of discharge 9 and patients who used inhaled anti-inflammatory medication within 100 days of discharge 11 had reduced risk of recurrent ED visits or hospitalizations over the following year. These previous controlled trials and observational studies examined the effect of starting controller medication at discharge or within a specific timeframe, but did not assess the effect of delay.
To further investigate the impact of initiating a controller after an acute asthma event, we assessed the association between receiving controller medication at discharge and risk of recurrent events; and the change in risk if controller initiation is delayed.
Methods

Data sources and patient sample
Two healthcare claims databases with de-identified medical and pharmacy data were used in this retrospective analysis: the Life Sciences Research Database and the IMPACT databases affiliated with OptumInsight; only OptumInsight data were used for patients appearing in both data sources. Administrative claims data in the Life Sciences Research Database includes medical claims, pharmacy claims, and eligibility information from a large national US health plan. The individuals covered by this health plan are geographically diverse across the US, with greatest representation in the South and Midwest US census regions. The plan provides fully insured coverage for professional (e.g., physician), facility (e.g., hospital), and outpatient prescription medication services. The IMPACT database contains similar data elements and geographic coverage, but includes data from over 46 health plans.
In order to focus on patients with persistent asthma (i.e., patients who would be candidates for a controller at ED/hospital discharge), commercial and Medicaid health plan members with evidence of an asthma-related ED visit or hospitalization followed by a controller fill were identified ( Fig. 1) A controller fill in the 6 months following the index date was required. Analysis was focused on patients whose first controller was an ICS, leukotriene modifier, or ICS/long-acting beta-agonist (LABA) combination 13 because only approximately 2% of patients with a qualifying index event filled a different type of controller first in the follow-up period. "On discharge" fills occurred 0 days post-index (discharge date) or they could be 1 day prior to discharge for patients with hospitalization index events.
In addition to the index event and follow-up controller requirements, patients were required to be at least 4 years of age and to be continuously enrolled in the health plan for the 12 months prior to the index date (baseline period) and 6 months following the index date. They were also required to have an asthma diagnosis in a primary or secondary diagnosis field and evidence of asthma treatment in the baseline period. Asthma treatment could have been quickrelief (SABAs, oral corticosteroids [OCS]) or controller medications (ICS, LABA, ICS/LABA combination, mast cell stabilizers, leukotriene modifiers, methylxanthines, immunomodulator). However, patients with claims history indicating controller pharmacy dispensing or administration within 6 months prior to the index event were excluded. This criterion was intended to reduce the possible influence of patients who might have been able to use controller medication from an earlier fill, but who did not have a controller dispensed immediately at discharge.
Patients who had an inpatient index event of more than 14 days duration or who had a diagnosis of cystic fibrosis (277.0x) or chronic obstructive pulmonary disease (491.0x, 491.1x , 491.2x , 491.8x, 491.9x, 492.xx, 494.xx, 496.xx, or filled prescription for anticholinergics) on a claim during the study period were excluded.
No identifiable protected health information was extracted or accessed during the course of the study. Pursuant to the Health Insurance Portability and Accountability Act, 14 the use of de-identified data does not require institutional review board approval or waiver of authorization.
Outcome measure
Asthma-related ED visits and hospitalizations during the 6-month post-index period (ie, recurrences) were identified using the same criteria as for the index event. Patients were observed until the first post-index recurrence or the end of the 6-month follow-up period.
Time-to-event analysis
Cox proportional hazards models of the time to first asthma-related ED visit or hospitalization were constructed. The primary predictor of interest was time without controller medication following discharge. Timeto-controller use was included as a time-varying covariate (ie, time-to-controller use interacted with elapsed time). The full primary model adjusted for data source, insurance type, age, sex, geographic region, index month/year, index season, index event, asthma as primary diagnosis for index event (yes/no), Charlson comorbidity index 15 (calculated based on baseline period claims), number of pre-index controller and rescue medication fills, and number of preindex all-cause and asthma-related ambulatory visits, ED visits, and hospitalizations (by definition, ED visits and hospitalizations must have been prior to the identification period).
Four sensitivity analyses were carried out. In the first, patients with events in the 2 weeks following the index event were excluded from the primary model in order to address concerns that these secondary events were related to the index event rather than a recurrence. In the second, patients with evidence of controller use in the year prior to the index date were excluded to address the possibility that patients might have had medication available from an earlier fill. The third sensitivity analysis stratified patients according to the index event (ED visit or hospitalization). In the fourth analysis, acute asthma-related office visits (defined as a physician or urgent care visit with asthma diagnosis followed by an OCS prescription fill or an asthmarelated office administration of systemic corticosteroid or SABA within 7 days following the visit) were added to the definition of "recurrence."
Two additional models were developed to characterize the pattern of change in risk with increasing delays. Controller initiation during 45-day increments following discharge was investigated in the first model. The 45-day increment was chosen empirically to ensure that the number of patients contributing data to each increment across the follow-up period was sufficient for meaningful analysis. In the second the hazard associated with a single day delay was determined. All models were adjusted for the same covariates.
Statistical analyses
Patient characteristics are presented descriptively. Means and standard deviations (SD) are provided for continuous variables. Wald confidence limits were estimated for the percentage of patients with a repeat asthma-related ED visit or hospitalization based on the normal approximation to the binomial distribution. Statistical significance in the Cox proportional hazards models was defined using a threshold of two-sided P < 0.05. All analyses were conducted using SAS 9.1 (SAS Institute, Cary, NC).
Results
Baseline and index event characteristics
A total of 6139 patients met all inclusion and exclusion criteria (Fig. 1) ; 55% were from the Life Sciences database and 45% from IMPACT. Patient sample baseline characteristics are shown in Table 1 . The mean (AESD) age was 22.4 AE 17.3 years and 55% were aged less than 18 years. For the overall sample, the mean Charlson comorbidity score was 1.14 AE 0.57 indicating relatively low comorbidity burden. In the pre-index period, 88% of patients filled a SABA, 51% filled an OCS, and 37% filled a controller (for controllers, fills occurred from 6 to 12 months pre-index).
Most index events were ED visits (78%) and fewer were hospitalizations (22%). For 90% of index events, asthma diagnosis was in the primary position on at least 1 claim. The duration of index hospitalizations ranged from 2 through 13 days (intraquartile range 3e4 days).
The controller and quick-relief medications patients received during follow-up are shown in Table 2 . Most patients (80%) filled an ICS as the first controller and 29% had a leukotriene modifier as their index controller (Table  2) . One-quarter (25%) of patients had evidence of controller initiation at discharge and 43% filled their first controller from 1 through 30 days post-discharge.
Recurrent events
Approximately 15% of patients (95%CI 14e16%) in the analysis had a repeat asthma-related ED visit or hospitalization within 6 months of the initial event. The fully adjusted Cox proportional hazards model for having a recurrent event, presented in Table 3 , shows that the risk increased as the time to initiate a controller increased. After adjustment, the estimated hazard ratio (HR) associated with not filling a controller at discharge was 1.79 (95% CI 1.42e2.25). The significant controller-by-time interaction (P < 0.001) indicates that the hazard increased with controller initiation delay. The change in the HR with increasing time-to-controller initiation is illustrated in Fig. 2 .
The sensitivity analyses did not substantially alter the interpretation of the results. Fully adjusted models excluding patients with events in the first 2 weeks following the index event (initial HR 1.33; 95%CI 0.97e1.83; with significant increase over time; P < 0.001) or excluding patients with claims for controllers in the year prior to the index date (initial HR 1.91; 95%CI 1.45e2.53; with significant increase over time; P < 0.001) yielded results similar to the primary model (Fig. 2) . Patients with an index ED event (initial HR 1.63; 95%CI 1.28e2.08; with significant increase over time; P < 0.001) or an index hospitalization (initial HR 1.67; 95%CI 0.77e3.60; with nonsignificant increase over time; P Z 0.10) also had HRs similar to the primary model (Fig. 2) . The reduced significance for the index hospitalization interaction term is likely due to the rarity of events, smaller sample size (n Z 1331), and reduced power to detect interaction effects. Allowing the subsequent event to be an ED visit, hospitalization, or acute asthma-related physician office visit also showed that recurrence risk increased if the controller was not initiated at discharge (initial HR 2.06; 95%CI 1.79e2.38) and that hazard increased with greater delay (P < 0.001).
The models of incremental delay showed that the risk of recurrent events remained relatively flat for controller initiation within the first 90 days and then increased thereafter. Specifically, the HRs for a recurrent ED visit or hospitalization for patients who initiated a controller within the first 45 days or from 46 through 90 days following discharge relative to those who received a controller at discharge were 2.30 (95%CI 1.86e2.85) and 2.51 (95%CI 1.88e3.35), respectively. The HR increased for patients starting a controller from 91 through 135 days following discharge (HR 5.46; 95%CI 3.97e7.52) and from 136 through 180 days following discharge (HR 8.13; 95%CI 5.16e12.79). The hazard for recurrent events for patients who received a controller the day after discharge was approximately triple that of patients who received a controller upon discharge (HR 2.95; 95%CI 1.48e5.88).
Discussion
This analysis of patients with persistent asthma who initiated a controller within 6 months following an asthmarelated ED visit or hospitalization suggests that recurrent events can be prevented by starting the controller immediately at discharge. Our findings are consistent with (10) 88 (9) 132 (10) 39 (10) 33 (14) 29 (15) 14 (9) 17 (13) Native Hawaiian/other Pacific Islander
Asian 50 (1) 15 (2) 26 (2) 1 (0) 4 (2) 1 (1) 2 (1) 1 (1) Hispanic 290 (9) 100 (11) 101 (7) 29 (8) 21 (9) 18 (9) 12 (8) (14) 388 (15) 97 (14) 70 (17) 68 (20) 35 (12) previous studies reporting that initiating a controller following a hospital event was associated with reduced recurrence risk. 8e12 Our analyses add to previous research by showing that even short delays were associated with increased risk of recurrent events, and risk accumulated as time elapsed.
A cause and effect relationship between delayed controller use and ED event/hospitalization recurrence is plausible, but we cannot exclude an alternative explanation: late filling of a controller prescription might also be a marker of impending exacerbation. That is, patients might respond to increasing symptoms by seeking additional asthma therapy. Although late controller prescription dispensing could be both a marker of exacerbation and a measure of lost therapeutic opportunity, we doubt that the former was a major factor in our findings. Recurrence risk is highest in the first few weeks following the index event and prescription filling behavior as a marker of recurrence would have obscured the time delay relationship we observed.
Although practice guidelines recommend that physicians consider initiating or continuing controller medication upon discharge for exacerbation events, 1,2 studies have shown that ED physicians infrequently prescribe controllers. 16, 17 A survey of pediatric emergency medicine physicians found that almost all thought that children with persistent asthma should be treated with long-term controllers, but less than 20% prescribed a controller at ED discharge. 16 The main reason for not prescribing was the belief that it was the responsibility of the primary care physician or asthma specialist. 16 Based on retrospective review of electronic medical records, Cydulka et al. 17 reported that 24% of patients who received ED treatment for an acute asthma exacerbation received an ICS upon discharge, but another 8% had a controller added in primary care within 6 months. Our study supports efforts to bridge the gap between acute and primary asthma care with ED or hospital-initiated prescribing of a controller prescription and patient education to reinforce the importance of filling and using controller medication upon discharge. 1, 2 Claims data provide information regarding real-world healthcare resource use, but analyses of these data are subject to certain limitations. Patients in the study were all managed care enrollees, and the findings might not generalize to uninsured populations. Claims provide evidence that prescriptions were filled, but whether patients used their medication as prescribed is not known. Thus, it is possible that some patients who filled controllers after their initial event were in fact untreated. Conversely, some patients we considered untreated might have had medication on hand from earlier fills. We mitigated the possible influence of such patients with eligibility rules excluding patients with recent controller fills and with sensitivity analysis. Our analyses did not include patients using controller therapy in the six months prior to the index event and we cannot be certain that the same recurrence phenomena would be seen in those continuously adherent to controller therapy.
Factors other than use of controller medications, such as the presence of exacerbation triggers including allergens, infections, or pollution, could influence the occurrence of asthma-related ED visits and hospitalizations. Although information on environmental factors was not available for this analysis, exposure to such triggers could vary by season or region and all of the proportional hazards models constructed for this study adjusted for these factors.
The data were limited in their ability to verify whether prescribing a controller upon discharge was clinically indicated for individual patients. Many different criteria have been used to define asthma exacerbations for research purposes, including clinical assessments of lung function, use of systemic corticosteroids, and the occurrence of asthma-related ED visits and hospitalizations. 18 Although quantifiable thresholds for lung function are included in definitions of severe exacerbations, 1,2 no measures of clinical severity (e.g., lung function) were available in this study and the degree of symptom worsening that brings a patient to the ED or hospital is subjective. However, guidelines recommend discharging patients with a daily controller when there is evidence of persistent asthma. 1, 19 Almost all asthma patients who have an ED visit or hospitalization meet these criteria and are candidates for a controller prescription upon discharge. 19 All patients included in our study filled a controller prescription within 6 months following an ED visit or hospitalization, which suggests that they had persistent asthma and were therefore candidates to receive a controller immediately. Practice guidelines recommend that patients with persistent asthma initiate a controller upon discharge from an acute asthma-related ED visit or hospitalization, and our findings support the importance of early initiation in reducing the risk of recurrence. Acute care providers should provide controller prescriptions to patients with persistent asthma after exacerbation events, and thereby help to bridge the gap between acute and primary care.
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